Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews · Hypertension

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 60%Moderate 2 · 40%High 0 · 0%

CCBs vs ACE inhibitor

Congestive heart failure · patients with hypertension

CCBs may leads to higher congestive heart failure compared with ACE inhibitor (low certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 1.16 [1.06, 1.28]
5 studies · 25276 participants
Low

CCBs vs ARB

Congestive heart failure · patients with hypertension

CCBs may leads to higher congestive heart failure compared with ARB (low certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 1.2 [1.06, 1.36]
5 studies · 23265 participants
Low

CCBs vs diuretics

Congestive heart failure · patients with hypertension

CCBs probably leads to higher congestive heart failure compared with diuretic (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 1.37 [1.25, 1.51]
5 studies · 34072 participants
Moderate

CCBs vs beta‐blocker

Congestive heart failure · patients with hypertension

CCBs showed no clear difference in congestive heart failure compared with β‐blocker (low certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.83 [0.67, 1.04]
2 studies · 19915 participants
Low

First‐line thiazides vs calcium channel blockers

Congestive heart failure · patients with hypertension

First‐line thiazides probably leads to lower total congestive heart failure Duration: 1 to 5 years compared with first‐line calcium channel blockers (moderate certainty).

1 finding from 1 review

First‐line diuretics versus other classes of antihypertensive drugs for hypertension 2023 · Cochrane Headline outcomes only
RR 0.74 [0.66, 0.82]
6 studies · 35217 participants
Moderate